Compare CVX & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVX | MRK |
|---|---|---|
| Founded | 1879 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.2B | 260.2B |
| IPO Year | N/A | N/A |
| Metric | CVX | MRK |
|---|---|---|
| Price | $149.99 | $99.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 15 |
| Target Price | ★ $172.13 | $110.33 |
| AVG Volume (30 Days) | 8.7M | ★ 15.5M |
| Earning Date | 10-31-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.56% | 3.41% |
| EPS Growth | N/A | ★ 58.08 |
| EPS | 7.09 | ★ 7.56 |
| Revenue | ★ $188,687,000,000.00 | $64,235,000,000.00 |
| Revenue This Year | N/A | $1.97 |
| Revenue Next Year | $3.14 | $4.96 |
| P/E Ratio | $21.15 | ★ $13.20 |
| Revenue Growth | N/A | ★ 1.68 |
| 52 Week Low | $132.04 | $73.31 |
| 52 Week High | $168.96 | $105.84 |
| Indicator | CVX | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 60.34 |
| Support Level | $149.26 | $100.31 |
| Resistance Level | $152.94 | $103.09 |
| Average True Range (ATR) | 2.36 | 2.92 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 22.17 | 55.90 |
Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with production of 3.0 million of barrels of oil equivalent a day, including 7.7 million cubic feet a day of natural gas and 1.7 million of barrels of liquids a day. Production activities take place in North America, South America, Europe, Africa, Asia, and Australia. Its refineries are in the US and Asia for total refining capacity of 1.8 million barrels of oil a day. Proven reserves at year-end 2024 stood at 9.8 billion barrels of oil equivalent, including 5.1 billion barrels of liquids and 28.4 trillion cubic feet of natural gas.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).